Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina
© Tuma et al; licensee BioMed Central Ltd. 2011
Received: 24 September 2011
Accepted: 26 October 2011
Published: 26 October 2011
Chronic refractory angina is a challenging clinical problem with limited treatment options. The results of early cardiovascular stem cell trials using ABMMC have been promising but have utilized intracoronary or intramyocardial delivery. The goal of the study was to evaluate the safety and early efficacy of autologous bone marrow derived mononuclear cells (ABMMC) delivered via percutaneous retrograde coronary sinus perfusion (PRCSP) to treat chronic refractory angina (CRA).
From May 2005 to October 2006, 14 patients, age 68 +/- 20 years old, with CRA and ischemic stress-induced myocardial segments assessed by SPECT received a median 8.19*108 ± 4.3*108 mononuclear and 1.65*107 ± 1.42*107 CD34+ cells by PRCSP..
ABMMC delivery was successful in all patients with no arrhythmias, elevated cardiac enzymes or complications related to the delivery. All but one patient improved by at least one Canadian Cardiovascular Society class at 2 year follow-up compared to baseline (p < 0.001). The median baseline area of ischemic myocardium by SPECT of 38.2% was reduced to 26.5% at one year and 23.5% at two years (p = 0.001). The median rest left ventricular ejection fraction by SPECT at baseline was 31.2% and improved to 35.5% at 2 year follow up (p = 0.019).
PRCSP should be considered as an alternative method of delivery for cell therapy with the ability to safely deliver large number of cells regardless of coronary anatomy, valvular disease or myocardial dysfunction. The clinical improvement in angina, myocardial perfusion and function in this phase 1 study is encouraging and needs to be confirmed in randomized placebo controlled trials.
An increasing number of patients with coronary artery disease remain symptomatic with disabling angina despite the optimal use of antianginal medications and percutaneous or surgical revascularization [1, 2]. Therapeutic angiogenesis is an experimental strategy utilizing angiogenic proteins, gene therapy or stem cells for inducing neovascularization of chronically ischemic myocardium [3, 4]. Currently, the majority of clinical studies investigating autologous bone marrow mononuclear cells (ABMMC) transplantation as a treatment for ischemic myocardium have been performed in patients with acute myocardial infarction using intracoronary delivery [5–11]. In contrast, in patients with refractory ischemia only a few trials have been published and all have used intramyocardial delivery [12–16]. Percutaneous retrograde coronary sinus perfusion (PRCSP) is a well-established technique for delivery of cardioplegia solution in cardiovascular surgery and for protection against myocardial ischemia in patients undergoing high risk percutaneous coronary intervention (PCI) [17–19]. Delivery by PRCSP has been shown to be a reasonable alternative to intracoronary and intramyocardial delivery in preclinical therapeutic angiogenesis models using both angiogenic proteins, gene therapy and stem cell therapy . The technique has the potential advantages of safety delivering a larger number of cells with more homogenious delivery across the myocardium to patients with refractory angina despite the presence of severe underlying coronary artery disease, valvular disease or previous myocardial infarction which may complicate delivery by either intracoronary or intramyocardial approach. The aim of the present study was to evaluate the safety of ABMMC delivered into the ischemic myocardium via PRCSP in patients with chronic refractory angina (CRA).
Patients with Canadian Cardiovascular Society (CCS) class III-IV angina despite maximal medical or surgical therapy who were ineligible for further percutaneous or surgical revascularization (based on coronary anatomy) and who had evidence for reversible ischemia on an exercise single photon emission computed tomography (SPECT) were enrolled. A committee comprising two cardiovascular surgeons and two interventional cardiologists determined the ineligibility for percutaneous or surgical revascularization. Patients with acute myocardial infarction, percutaneous or surgical revascularization within six months of enrollment in the study, a history of malignant disease, severe renal dysfunction, or unexplained hematology or biochemical abnormalities were excluded. The local ethics committee at Clinica Maison de Sante and Centro Cardiovascular San Nicolá s approved the protocol and all patients gave informed consent. The review and analysis of the data was also approved by the IRB at the University of Utah.
The baseline screening assessment of patients included clinical evaluation, electrocardiogram (ECG), laboratory evaluation (complete blood count, blood chemistry, erythrocyte sedimentation rate, creatine kinase, and troponin T serum levels). Patients kept a record of daily angina frequency for three weeks, and the severity of angina was graded according to the CCS class at baseline, 3, 12, and 24 months. Within two weeks prior to cell therapy, exercise capacity was evaluated using bicycle ergometry in conjunction with SPECT imaging to assess myocardial ischemia and left ventricular (LV) function.
Patients had complete blood count, creatine kinase levels and ECG performed immediately prior to and immediate after the procedure. Complete blood count, creatine kinase, and troponin T levels were also assessed eight hours post procedure with an ECG prior to discharge. All patients were monitored in the cardiac intensive care unit for 12 hours after the procedure and were discharged the following day. A transthoracic echocardiogram was performed prior to discharge to detect the presence of pericardial effusion. The clinical follow-up evaluations including the laboratory tests described above were performed 3, 12 and 24 months after the injection procedure. At 12 and 24 months of follow-up exercise bicycle testing, and gated SPECT were performed.
Assessment of exercise capacity
All patients performed a symptom-limited bicycle exercise test with a 20-W starting load and 10-W increments per minute at baseline and at 12 and 24 months after the injection procedure. Antianginal medication was continued. The test points were angina pectoris, physical exhaustion, dyspnea, significant decrease in blood pressure (10 mmHg), or achievement of maximal age-related heart rate. A 12-lead ECG was recorded before, during, and after the test. The total exercise duration, maximal workload achieved in percentages (expected for age, gender, height, and weigh) at baseline was compared to 12 and 24 months after ABMMC delivery.
Single-photon emission computed tomography
For the SPECT examination, a one-day rest-stress protocol was used. On the same day, images at rest were obtained 60 minutes after the 99 mTechnetium Sestamibi injection using a double-head SPECT camera as previously described. (17,18) Using the bicycle exercise test, 99 mTechnetium Sestamibi was injected intravenously at peak exercise (85% of the estimated heart rate) which was continued for 2 minutes after tracer injection and images were obtained 30 minutes after the stress test. Reconstruction yielded long-and short -axis projections perpendicular to the heart axis. The short-axis slices were displayed in polar map format.
Bone marrow aspiration and isolation of mononuclear cells
A volume of 300 ml of bone marrow was harvested from the iliac crest under local anesthesia and placed in heparinized Hanks' balanced salt solution. ABMMC were isolated by Hess 6% density gradient centrifugation with a final suspension volume of 50 ml and a mean cell concentration of 8.19*108 ± 4.3*108 mononuclear cells and 1.65*107 ± 1.42*107 CD34+ cells.
Data are reported as median ± SDs. Quantitative data were compared using a paired, 2 tailed Student's test. Categorical data were compared using the Wilconxon signed rank test, a p < 0.05 was considered significant.
The baseline clinical characteristics of the 14 enrolled RA patients are listed in Table 1. All patients had three vessel disease and were deemed ineligible for further revascularization by the screening committee of physicians. The patient's antianginal regimen was not changed during the 24 month follow-up.
Baseline Clinical Demographics
(N = 14)
Systemic Hypertension - N (%)
Hyperlipidemia - N (%)
Diabetes Mellitus - N (%)
Previous myocardial infarction - N (%)
Previous percutaneous coronary intervention - N (%)
Previous coronary artery bypass surgery - N (%)
Myocardial perfusion by SPECT
Analysis pre and post ABMMC transplantation: Canadian Cardiovascular Society class, rest left ventricular ejection faction and ischemic myocardium percent
(N = 14)
(N = 13)
(N = 13)
REST Global LVEF* (%)
Ischemic Myocardium (%) Median
LV Function assessed by SPECT
This study demonstrates that ABMMC delivered by PRCSP in patients with CRA and stress-inducible ischemia was safe, may reduce anginal symptoms and improve exercise capacity. Stem cell transplantation by PRCSP is an alternative route of delivery to the myocardium for patients with coronary artery occlusion at their initial portions, or for patients with severe multivessel disease or occluded venous and arterial grafts. In this study we have demonstrated that, in patients with chronic ischemia with or without severely impaired LV function, that ABMMC injection enhances myocardial perfusion. In addition we observed that improved systolic LV function occurred only in patients with low ejection at baseline. Improvement and maintenance of the LV ejection fraction at 24 months follow-up was most likely a result of increased myocardial perfusion and global regional wall motion. This resulted in a reduced LV end-systolic volume. Consequently, the therapeutic effect appears to be more related to enhanced myocardial contractility rather than induction of LV reverse remodeling. The findings of the present study are consistent with the hypothesis that ABMMC promote angiogenesis, resulting in increased myocardial perfusion . The present study was not designed to assess the underlying cellular mechanism of bone marrow cell injection improving myocardial perfusion and LV function. Therefore, secretion of pro-angiogenic factors by the bone marrow cells and differentiation of bone marrow cells in endothelium cells, smooth muscle cells, or cardiomyocytes could have contributed to the described effect. The mechanism of angiogenesis could be caused by differentiation of bone marrow cells in endothelial and/or vascular smooth muscle cells or by the production of angiogenic cytokines, as previously proposed but has not been fully validated . ABMMC by the PRCSP has been proposed as a novel therapeutic option for patients with coronary artery disease. Until now most clinical studies investigating ABMMC were performed in patients with acute myocardial infarction. Data from patients with chronic ischemia are scarce. At present, only few studies in patients with chronic coronary artery disease have been published [9–13]. The current results are in line with studies on the safety and feasibility of intramyocardial delivery of ABMMC in patients with chronic ischemia and angina pectoris. Tse et al 9 described a reduction in anginal symptoms, improved wall motion and improved wall thickening at 3 'months follow-up in 8 patients. In addition, the area of hypoperfused myocardium was reduced on SPECT. Fuchs et al reported a reduction in anginal symptoms and improved myocardial perfusion in 27 patients with a trend toward improved LV ejection fraction . Perin et al reported the same results in 21 patients . In a randomized controlled study Losordo et al demonstrated data that CD34 + after GCSF can be safely transplanted via intramyocardial injection and may improve perfusion and reduce symptoms in patients with advanced coronary disease . In this pilot trial ABMMC were successfully delivered in each patient without any major periprocedural events (i.e., death, myocardial infarction, ventricular arrhythmias, cardiac perforation, pericardial effusion or significant enzyme release) using PRCSP. The present study supports previously suggested beneficial effects in preclinical models of retrograde stem cells delivery for cardiac disease,[21, 22] and the first to demonstrate improvement on symptoms, perfusion defects and LV function by PRVST in patients with preserved or decreased LV ejection fraction. However, we found similar improvements in patients with chronic ischemia with or without severely impaired LV function. This study suggests improvement and potential outcome durability of angina symptoms relief and better angina class, myocardial perfusion and contractility with this therapeutic approach in chronic refractory angina patients. We believe there may be clinical potential for this relatively novel method of cell delivery for patients suffering from refractory angina. We currently have a number of clinical trials using retrograde delivery of cells for both chronic refractory angina and heart failure based on this trial. Larger randomized trials will be needed to determine optimal cell numbers and to further understand the clinical outcomes.
autologous bone marrow mononuclear cells
Canadian Cardiovascular Society
percutaneous retrograde coronary sinus perfusion
single photon emission computed tomography.
- Jolicoeur EM: Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. American heart journal. 2008, 155 (3): 435-44. 10.1016/j.ahj.2007.12.005.View ArticlePubMedGoogle Scholar
- Mannheimer C: The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. European heart journal. 2002, 23 (5): 355-70. 10.1053/euhj.2001.2706.View ArticlePubMedGoogle Scholar
- Strauer BE: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002, 106 (15): 1913-8. 10.1161/01.CIR.0000034046.87607.1C.View ArticlePubMedGoogle Scholar
- Wollert KC: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004, 364 (9429): 141-8. 10.1016/S0140-6736(04)16626-9.View ArticlePubMedGoogle Scholar
- Schachinger V: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. Journal of the American College of Cardiology. 2004, 44 (8): 1690-9. 10.1016/j.jacc.2004.08.014.View ArticlePubMedGoogle Scholar
- Chen SL: Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American journal of cardiology. 2004, 94 (1): 92-5. 10.1016/j.amjcard.2004.03.034.View ArticlePubMedGoogle Scholar
- Schachinger V: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. The New England journal of medicine. 2006, 355 (12): 1210-21. 10.1056/NEJMoa060186.View ArticlePubMedGoogle Scholar
- Janssens S: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006, 367 (9505): 113-21. 10.1016/S0140-6736(05)67861-0.View ArticlePubMedGoogle Scholar
- Lipinski MJ: Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. Journal of the American College of Cardiology. 2007, 50 (18): 1761-7. 10.1016/j.jacc.2007.07.041.View ArticlePubMedGoogle Scholar
- Tse HF: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003, 361 (9351): 47-9. 10.1016/S0140-6736(03)12111-3.View ArticlePubMedGoogle Scholar
- Fuchs S: Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. Journal of the American College of Cardiology. 2003, 41 (10): 1721-4. 10.1016/S0735-1097(03)00328-0.View ArticlePubMedGoogle Scholar
- Perin EC: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003, 107 (18): 2294-302. 10.1161/01.CIR.0000070596.30552.8B.View ArticlePubMedGoogle Scholar
- Briguori C: Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. American heart journal. 2006, 151 (3): 674-80. 10.1016/j.ahj.2005.04.033.View ArticlePubMedGoogle Scholar
- Losordo DW: Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circulation research. 2011, 109 (4): 428-36. 10.1161/CIRCRESAHA.111.245993.PubMed CentralView ArticlePubMedGoogle Scholar
- Giordano FJ: Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart?*. Journal of the American College of Cardiology. 2003, 42 (6): 1129-31. 10.1016/S0735-1097(03)00903-3.View ArticlePubMedGoogle Scholar
- Boekstegers P: Selective suction and pressure-regulated retroinfusion: an effective and safe approach to retrograde protection against myocardial ischemia in patients undergoing normal and high risk percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology. 1998, 31 (7): 1525-33. 10.1016/S0735-1097(98)00135-1.View ArticlePubMedGoogle Scholar
- Pohl T: Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2004, 62 (3): 323-30. 10.1002/ccd.20060.View ArticleGoogle Scholar
- Raake P: Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. Journal of the American College of Cardiology. 2004, 44 (5): 1124-9. 10.1016/j.jacc.2004.05.074.View ArticlePubMedGoogle Scholar
- von Degenfeld G: Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. Journal of the American College of Cardiology. 2003, 42 (6): 1120-8. 10.1016/S0735-1097(03)00915-X.View ArticlePubMedGoogle Scholar
- Hoshino K: Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres. Gene therapy. 2006, 13 (18): 1320-7. 10.1038/sj.gt.3302793.View ArticlePubMedGoogle Scholar
- Hou D: Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 2005, 112 (9 Suppl): I150-6.PubMedGoogle Scholar
- George JC: Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction. Journal of interventional cardiology. 2008, 21 (5): 424-31. 10.1111/j.1540-8183.2008.00390.x.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.